WG Considerations; Updates to the 2018-19 Recommendations

Lisa Grohskopf, MD, MPH
Influenza Division, CDC
Advisory Committee on Immunization Practices

June 20, 2018
Acknowledgments

Influenza Division
Noreen Alabi
Lenee Blanton
Lynnette Brammer
Joe Bresee
Alicia Budd
Jessie Chung
Jill Ferdinands
Brendan Flannery
Alicia Fry
Dan Jernigan
Jackie Katz
Krista Kniss
Natalie Kramer
Desiree Mustaquim
Sonja Olsen
Leslie Sokolow
Calli Taylor
Jerry Tokars
Tim Uyeki

Immunization Safety Office
Karen Broder
Frank Destefano
Penina Haber
Tom Shimabukuro

Immunization Services Division
Sam Graitcer
Andrew Kroger
Amy Parker Fiebelkorn
Jeanne Santoli
WG Considerations and Ongoing Discussions

- **Considerations**
  - 2017-18 season safety data reassuring
  - Discussion regarding quadrivalent adjuvanted vaccine for young children:
    - Reactogenicity
    - Very limited data on coadministration with other vaccines

- **Ongoing discussions**
  - Vaccine efficacy/effectiveness
    - LAIV4
    - Egg-based vs. non egg-based vaccines
    - Vaccines for persons aged 65 years and older
  - Surveillance, safety and vaccine coverage updates
2018-19 ACIP Influenza Recommendations—Core Recommendation:

- Re-iterates core recommendation that annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications.
2018-19 ACIP Influenza Recommendations—Updates: Vaccine Composition for 2018-19

- **U.S. Influenza vaccine composition for 2018-19**
  - **Trivalent Vaccines**
    - A/Michigan/45/2015 (H1N1)pdm09-like virus
    - A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus—updated
    - B/Colorado/06/2017-like virus (Victoria lineage)—updated
  - **Quadrivalent Vaccines**
    - Above three, plus B/Phuket/3073/2013-like virus (Yamagata lineage)
2018-19 ACIP Influenza Recommendations—Updates: FluMist Quadrivalent (LAIV4)

- New language approved by ACIP at vote in February 2018
  - For the 2018-19 season, providers may choose to administer any licensed, age-appropriate influenza vaccine (IIV, RIV4, or LAIV4). LAIV4 is an option for those for whom it is otherwise appropriate.

- Updated VE estimates for LAIV4 will be presented as they become available

- Contraindications and precautions remain the same as previously

- LAIV4 is acceptable for persons with a history of egg allergy (approved by ACIP in February 2016, prior to the decision to not recommend use of LAIV4 for 2016-2017)
2018-19 ACIP Influenza Recommendations—Updates: New Products/Licensure Changes

- Fluarix Quadrivalent (IIV4, GSK)
  - 0.5mL dose licensed for children aged ≥6 months (previously licensed for ≥3 years) in January 2018
  - Data presented to ACIP in February 2018
  - Three inactivated influenza vaccines licensed for 6- through 35-month-olds:
    - Fluarix Quadrivalent (IIV4, GSK)—0.5mL dose
    - FluLaval Quadrivalent (IIV4, GSK)—0.5mL dose
    - Fluzone Quadrivalent (IIV4, Sanofi Pasteur)—0.25mL dose
2018-19 Influenza Recommendations
Discussion and Vote:

Reaffirm the seasonal influenza recommendations for the 2018-2019 season
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.